Selected article for: "adjuvant delivery system and delivery system"
Author: Criscuolo, E.; Caputo, V.; Diotti, R. A.; Sautto, G. A.; Kirchenbaum, G. A.; Clementi, N.
Title: Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines
  • Document date: 2019_3_4
    • ID: 0xo2fiop_26
    Snippet: Moreover, the increased immunogenicity of this delivery system could be explained by the adjuvant activity of β-glucans on the yeast cell wall, which demonstrates immunomodulatory and adjuvant effects through binding of innate pathogen receptors on macrophages, DC, and neutrophils [71] . Currently, two clinical trials have been developed: GS-4774 for HBV treatment and GI-5005 for hepatitis C virus (HCV) treatment (Table 2 ). Regarding the clinic.....
    Document: Moreover, the increased immunogenicity of this delivery system could be explained by the adjuvant activity of β-glucans on the yeast cell wall, which demonstrates immunomodulatory and adjuvant effects through binding of innate pathogen receptors on macrophages, DC, and neutrophils [71] . Currently, two clinical trials have been developed: GS-4774 for HBV treatment and GI-5005 for hepatitis C virus (HCV) treatment (Table 2 ). Regarding the clinical trial for GS-4774, despite the positive results obtained from phase 1 [72] , the second phase, conducted in virally suppressed, noncirrhotic patients with chronic HBV infection did not show a clinical benefit. However, other safety and efficacy studies have been conducted on another group of patients (in particular, in treatment-naïve patients with chronic HBV) [73] . Regarding the clinical trial for GI-5005, phases I and II reported promising results [74] . In particular, in this trial, GI-5005 was used also in combination with Peg-IFN/ribavirin. However, data on efficacy have not been published yet.

    Search related documents:
    Co phrase search for related documents
    • HCV treatment and treatment naïve: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • increase immunogenicity and promising result: 1
    • innate pathogen receptor and pathogen receptor: 1, 2, 3, 4, 5, 6, 7, 8
    • particular patient group and patient group: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • patient group and positive result: 1, 2
    • patient group and second phase: 1
    • patient group and treatment naïve: 1, 2
    • patient group and yeast cell wall: 1
    • positive result and promising result: 1
    • positive result and second phase: 1, 2